

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM671438

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
RESUBMIT DOCUMENT ID:	900638301

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Goldman Sachs Specialty Lending Group, L.P.		08/19/2021	Limited Partnership: NEW YORK

RECEIVING PARTY DATA

Name:	CutisPharma, Inc.
Street Address:	8 Cabot Road
Internal Address:	Suite 2000
City:	Woburn
State/Country:	MASSACHUSETTS
Postal Code:	01801
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 10

Property Type	Number	Word Mark
Registration Number:	3275609	FIRST
Registration Number:	2636155	FIRST RX
Registration Number:	4416915	ORAL SUSPENSION
Registration Number:	4678283	ORAL SOLUTION
Registration Number:	4416916	SUPPOSITORY
Registration Number:	5055386	TRANSFORMING COMPOUNDING THROUGH INNOVAT
Registration Number:	5360667	TRANSFORMING MEDICINE THROUGH INNOVATION
Registration Number:	5244475	FIRST
Registration Number:	4473417	CUTISPHARMA
Registration Number:	4420640	CP

CORRESPONDENCE DATA

Fax Number: 9198216800

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (919) 838-2034

Email: pkarmire@smithlaw.com

Correspondent Name: Perky L. Kamire / Smith Anderson Law

TRADEMARK

Address Line 1:	150 Salisbury Street
Address Line 2:	Suite 2300
Address Line 4:	Raleigh, NORTH CAROLINA 27601

NAME OF SUBMITTER:	Perky L. Karmire
---------------------------	------------------

SIGNATURE:	//s/ Perky L. Karmire
-------------------	-----------------------

DATE SIGNED:	08/31/2021
---------------------	------------

Total Attachments: 4

source=Goldman Sachs - USPTO TMSA Termination of 3.21.18 and 4_21_20 IPSA #page1.tif

source=Goldman Sachs - USPTO TMSA Termination of 3.21.18 and 4_21_20 IPSA #page2.tif

source=Goldman Sachs - USPTO TMSA Termination of 3.21.18 and 4_21_20 IPSA #page3.tif

source=Goldman Sachs - USPTO TMSA Termination of 3.21.18 and 4_21_20 IPSA #page4.tif

**TERMINATION AND RELEASE
OF
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Termination and Release”) dated as of August 19, 2021, is made by Goldman Sachs Specialty Lending Group, L.P., as Collateral Agent (“Grantee”), in favor of CutisPharma, Inc. (“Grantor”). Capitalized terms used in this Termination and Release and not otherwise defined herein have the meanings specified in the Intellectual Property Security Agreement (defined below).

WITNESSETH:

WHEREAS, pursuant to that certain Trademark Security Agreement dated as of March 21, 2018, by and between Grantor and Grantee, Grantor executed that certain Intellectual Property Security Agreement in United States Trademarks, effective as of March 21, 2018 (the “Trademark Security Agreement”), which was recorded in the United States Patent and Trademark Office on March 21, 2018 at Reel 006296 / Frame 0780, pursuant to which Grantor granted a security interest to Lenders in Grantor’s Trademarks, including certain trademarks and/or trademark applications listed on Exhibit A attached hereto and made a part hereof.

WHEREAS, pursuant to Grantor’s name change, effective as of January 22, 2020, Grantor filed a Change of Name with the United State Patent and Trademark Office which was recorded in the United States Patent and Trademark Office on April 21, 2020 at Reel 006919 / Frame 0944, pursuant to which Grantor granted a security interest to Lenders in Grantor’s Trademarks, including certain trademarks and/or trademark applications listed on Exhibit A attached hereto and made a part hereof.

WHEREAS, Grantee now desires to terminate and release its security interest in the Trademarks listed on Exhibit A attached hereto and reassign any and all rights, title, and interest in the same to Grantor;

NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged:

1. Grantee hereby releases its security interest in all of Grantor’s right, title and interest in and to the Trademarks set forth on Exhibit A.
2. If and to the extent that Grantee has acquired any right, title or interest in or to any of the Trademarks set forth on Exhibit A, Grantee hereby reassigns, grants and conveys to Grantor, without any representation, warranty, recourse or undertaking by Grantee, any and all of Grantee’s right, title, and interest in and to such Trademarks.

[signature page follows]

IN WITNESS WHEREOF, Grantee has caused this Termination and Release to be duly executed and delivered as of the date first written above.

GOLDMAN SACHS BANK USA, AS
COLLATERAL AGENT

By: _____
Name: _____
Title: _____







Greg Watts
Authorized Signatory


[Signature Page to Trademark Security Agreement Release (Goldman Sachs)]

TRADEMARK
REEL: 007404 FRAME: 0861

EXHIBIT A

U.S. Trademark Registrations/Applications

OWNER	TRADEMARK	APPLICATION NUMBER / REGISTRATION NUMBER	APPLICATION DATE / REGISTRATION DATE
AZURITY PHARMACEUTICALS, INC.	 CP	85688748 4420640	7/27/12 10/22/13
AZURITY PHARMACEUTICALS, INC.	CUTISPHARMA	85688718 4473417	7/27/12 1/28/14
AZURITY PHARMACEUTICALS, INC.	 FIRST	87136398 5244475	8/12/16 7/18/17
AZURITY PHARMACEUTICALS, INC.	 FIRST	76418087 3275609	6/7/02 8/7/07
AZURITY PHARMACEUTICALS, INC.	 FIRST RX	75882933 2636155	12/29/99 10/15/02
AZURITY PHARMACEUTICALS, INC.	 ORAL SUSPENSION	85688764 4416915	7/27/12 10/15/13
AZURITY PHARMACEUTICALS, INC.	 ORAL SOLUTION	86299917 4678283	6/4/14 1/27/15

OWNER	TRADEMARK	APPLICATION NUMBER / REGISTRATION NUMBER	APPLICATION DATE / REGISTRATION DATE
AZURITY PHARMACEUTICALS, INC.	 SUPPOSITORY	85688790 4416916	7/27/12 10/15/13
AZURITY PHARMACEUTICALS, INC.	TRANSFORMING COMPOUNDING THROUGH INNOVATION	86540574 5055386	2/20/15 10/4/16
AZURITY PHARMACEUTICALS, INC.	TRANSFORMING MEDICINE THROUGH INNOVATION	87006120 5360667	4/19/16 12/19/17